Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension

Freiberg, Josefine Clement; Spreckelsen, Alexander von; Kolko, Miriam; Azuara‐Blanco, Augusto; Virgili, Gianni

doi:10.1002/14651858.cd013817.pub2

Cited by 14 publications

(17 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rho kinase inhibitors are another molecule that continues to be studied as a treatment that effectively lowers IOP by modulating the drainage of aqueous humor through the trabecular network and Schlemm canal. 41 Adenosine receptor agonists and nitric oxide donors are also new drugs targeting the conventional outflow system for the treatment of ocular hypertension in glaucoma. 42…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Schlemm Canal Parameters Using Swept-Source Optical Coherence Tomography in Eyes That Underwent Keratoplasty

Bolac

Köse

İmamoğlu

et al. 2023

Eye &Amp; Contact Lens: Science &Amp; Clinical Practice

View full text Add to dashboard Cite

Objectives: In this study, we aimed to evaluate Schlemm canal parameters using anterior segment swept-source optical coherence tomography in eyes that underwent keratoplasty and compare them with keratoconus and healthy control groups. Methods: The study included 32 patients who underwent penetrating keratoplasty or deep anterior lamellar keratoplasty once due to keratoconus and age-matched and sex-matched 20 keratoconus patients and 30 healthy controls. In all the patients, a single horizontal image centered on the central cornea was obtained from the nasal and temporal quadrants with low-intensity scanning to visualize Schlemm canal. Results: There was no statistically significant difference between the groups for age and gender (P˃0.05). In the keratoplasty group, the area and diameter of Schlemm canal were 2.266±1.141μm2 and 160.77±65.08 μm, respectively, in the nasal quadrant and 2.623±1.277 μm2 and 158.81±68.05 μm, respectively in the temporal quadrant, which were statistically significantly lower compared with other groups (P<0.001 for all). There was no significant difference between the penetrating and deep anterior lamellar keratoplasty subgroups for Schlemm canal parameters. Conclusion: This is the first study to report anterior segment optical coherence tomography after surgery shows SC parameters that are, on average, less than age-matched and keratoconus controls.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Schlemm Canal Parameters Using Swept-Source Optical Coherence Tomography in Eyes That Underwent Keratoplasty

Bolac

Köse

İmamoğlu

et al. 2023

Eye &Amp; Contact Lens: Science &Amp; Clinical Practice

View full text Add to dashboard Cite

show abstract

“…The IOP-lowering effect of prostaglandins is superior to other classes of topical IOP-lowering drugs [57,58], followed by nonselective β-blockers, α-adrenergic agonists, selective β-blockers, and topical CAIs [59]. The newer class of ROCK inhibitors, netarsudil is less efficacious in reducing IOP compared to latanoprost or timolol [60], hence it would find a place alongside or between adrenergic agonists and topical CAIs.…”

Section: Iop-lowering Effectmentioning

confidence: 99%

“…Netarsudil 0.02% is prescribed as a once-daily dose, whereas ripasudil is given in twice-daily doses. The IOP reduction with these drugs is between 15 and 25% [60]. Within the class of ROCK inhibitors, netarsudil once daily reduced IOP more effectively compared to ripasudil twice daily [60].…”

Section: Iop-lowering Effectmentioning

confidence: 99%

“…The IOP reduction with these drugs is between 15 and 25% [60]. Within the class of ROCK inhibitors, netarsudil once daily reduced IOP more effectively compared to ripasudil twice daily [60].…”

Section: Iop-lowering Effectmentioning

confidence: 99%

“…ROCK inhibitors, netarsudil 0.02% is indicated in a once-daily dose, whereas ripasudil is given twice-daily. The IOP reduction with these drugs is between 15 and 25% in open-angle glaucoma and ocular hypertension [60]. Ripasudil effectively reduced IOP in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma [156].…”

Section: Choice Of Therapymentioning

confidence: 99%

See 2 more Smart Citations

An Update on Pharmacotherapy of Glaucoma

Virani¹,

Rewri²

2023

Preprint

View full text Add to dashboard Cite

Progressive loss of retinal ganglionic cells (RGC) causes blindness in glaucoma. Elevated intraocular pressure (IOP) is the most important, treatable risk factor. Currently, the management of glaucoma is centred at reducing the IOP, and drugs in the form of topical drops are the first line of management. Drugs reduce IOP either by suppressing aqueous humour secretion or improving the aqueous humour outflow. Newer drugs added during the past three decades to the armamentarium of glaucoma treatment have targeted the aqueous outflow. With an evolving understanding of the pathogenesis of glaucoma, the role of 24-hour IOP control and other IOP-independent risk factors affecting ocular blood flow and RGC toxicity is also recognised. The role of available drugs in controlling IOP over 24-hours is being evaluated. Improvement of ocular blood flow and neuroprotection are seen as potential drug targets in preventing the loss of RGC. In this article, we review the pharmacotherapy of glaucoma based on current therapeutic principles.

show abstract